PTC Therapeutics agrees to buy Sangamo’s ST-920 Fabry gene therapy assets for $111 million upfront
PTCT•PTC to acquire Sangamo’s ST-920 Fabry program
- PTC Therapeutics entered an asset purchase agreement to buy Sangamo’s ST-920 gene therapy program for Fabry disease.
- Deal terms include an upfront payment of $111 million, with up to $100 million tied to FDA accelerated approval and full approval milestones.
- Closing hinges on Delaware bankruptcy court authorization, Hart-Scott-Rodino clearance, and other customary conditions.
- A bankruptcy court hearing on the transaction is scheduled for Sept. 10, 2026, with an outside closing date of Oct. 15, 2026.
